Evidence map›Paper›PMID 41959238›Full record

ArticlebioRxiv : the preprint server for biology2026

Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction.

Jenna B Mendelson, Jacob Sternbach, Minwoo Kim, Rashmi M Raveendran, Ryan A Moon, Lynn M Hartweck, Walt Tollison, John P Carney, Todd Markowski, LeeAnn Higgins and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jenna B MendelsonDepartment of Integrative Biology and Physiology, University of Minnesota.ORCID 0000-0002-8229-385X
Jacob SternbachLillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota.
Minwoo KimLillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota.
Rashmi M RaveendranLillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota.
Ryan A MoonLillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota.
Lynn M HartweckLillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota.
Walt TollisonExperimental Surgical Services, Department of Surgery, University of Minnesota.
John P CarneyExperimental Surgical Services, Department of Surgery, University of Minnesota.
Todd MarkowskiCenter for Metabolomics and Proteomics, Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota.
LeeAnn HigginsCenter for Metabolomics and Proteomics, Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota.
Sally E PrinsGazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina.
Felipe KazmirczakAllina Health Minneapolis Heart Institute, Abbott Northwestern Hospital.
Kurt W PrinsGazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina.ORCID 0000-0002-0364-6742

Funding

GP130 Antagonism in Porcine RV Pressure OverloadR01HL162927 · NHLBI · UNIVERSITY OF MINNESOTA · PI Kurt W Prins · 2022 to 2026
$3.3M
Multi-scale Investigation of Sex Differences in Right Ventricular Function via Estrogen-Microtubule InteractionsR01HL158795 · NHLBI · UNIVERSITY OF MINNESOTA · PI Kurt W Prins · 2022 to 2026
$2.8M
Mechanisms of Large Animal RV DysfunctionF31HL170585 · NHLBI · UNIVERSITY OF MINNESOTA · PI MENDELSON, JENNA BLAIR · 2024 to 2025
$71k
NHLBI NIH HHS F31 HL170585NHLBI NIH HHS R01 HL158795NHLBI NIH HHS R01 HL162927
6 · The paper itself

Abstract

Background: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multi-omic evaluation of pulmonary artery banded (PAB) pigs with differing degrees of RV compromise. Methods: PAB pigs were stratified into mild and severe RVD groups using an RV ejection fraction cutoff of 35%. RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multi-omic findings. Results: Cardiac MRI revealed progressive structural and functional alterations in mild and severe RVD pigs. snRNAseq demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, co-localization patterns in RV sections, and ectopic cardiomyocyte HIF1 expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared to severe RVD. Finally, integration of multi-omic approaches identified insufficient mitochondrial unfolded protein response, impaired macrophage efferocytosis, and activation of the ribotoxic stress response as potential contributors to severe RVD. Conclusions: Our multi-omic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RV dysfunction. Future studies are needed to determine how targeting these pathways influences RV phenotypes.

Identifiers

PMID41959238
PMCPMC13060959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.